Humana is seeing aggressive analyst upgrades, including a move to Buy from Hold and a near doubling of the price target to $441. Another firm raised its price target to $335 while keeping an Outperform rating, citing a reduced likelihood of negative medical loss ratio shifts through 2026. The bullish outlook centers on a stabilizing managed care market and expectations that Humana’s Medicare star ratings will recover. Star ratings influence bonus payments, premium positioning, and plan selection during the Annual Election Period. 2026 is framed as an earnings bottom and a rebasing year, contingent on star ratings results in October. Recent performance includes Q1 2026 adjusted EPS of $10.31 on $39.65 billion revenue, with Individual Medicare Advantage membership up 22% year to date and an insurance segment benefit ratio of 89%.
"Deutsche Bank just delivered one of the most aggressive analyst upgrades of 2026 on Humana, lifting the managed care giant to Buy from Hold while nearly doubling its price target to $441 from $235. The move signals that one of Wall Street's more cautious voices now sees a fundamental reset in the Humana franchise."
"Mizuho raised its Humana price target to $335 from $290 and kept an Outperform rating, citing a reduced likelihood of negative medical loss ratio shifts through 2026. For prudent investors weighing a healthcare rebound trade, the upgrade reframes Humana stock as a recovery story rather than a falling knife."
"Deutsche Bank's thesis rests on a stabilizing managed care market and an expectation that Humana's Medicare star ratings will recover. Star ratings drive bonus payments, premium positioning, and enrollee plan selection during Annual Election Period shopping. The firm also frames 2026 as the earnings bottom and a rebasing year, depending on the stars results in October."
"Humana is a Louisville-based managed care leader anchored by Individual Medicare Advantage, CenterWell Primary Care, and CenterWell Pharmacy Solutions. Q1 2026 results beat on both lines, with adjusted EPS of $10.31 on revenue of $39.65 billion, up 24% year over year. Individual Medicare Advantage membership climbed 22% year to date, and the insurance segment benefit ratio came in at 89%, slightly favorable to guidance."
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]